Today’s Stock On Watch: What Will Happen to Aegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Next? The Stock Has Decline in Shorts

November 23, 2016 - By kentuckypostne   ·   0 Comments

Today's Stock On Watch: What Will Happen to Aegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) Next? The Stock Has Decline in Shorts

The stock of Aegerion Pharmaceuticals Incorporated (NASDAQ:AEGR) registered a decrease of 7.23% in short interest. AEGR’s total short interest was 3.29 million shares in November as published by FINRA. Its down 7.23% from 3.55 million shares, reported previously. With 228,800 shares average volume, it will take short sellers 14 days to cover their AEGR’s short positions. The short interest to Aegerion Pharmaceuticals Incorporated’s float is 25.15%. The stock last traded at $1.89 per share. It is down 38.64% since April 21, 2016 and is downtrending. It has underperformed by 43.97% the S&P500.

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical firm engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The company has a market cap of $55.84 million. It operates through pharmaceuticals segment. It currently has negative earnings. The Company’s products include lomitapide and metreleptin.

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Ratings Coverage

Out of 5 analysts covering Aegerion Pharmaceuticals (NASDAQ:AEGR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. Aegerion Pharmaceuticals has been the topic of 9 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Guggenheim given on Monday, December 21. Bank of America upgraded Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) on Wednesday, November 11 to “Neutral” rating. On Tuesday, July 28 the stock rating was upgraded by Jefferies to “Buy”. The firm earned “Underperform” rating on Friday, February 12 by Bank of America. The company was upgraded on Friday, August 7 by Zacks.

AEGR Company Profile

Aegerion Pharmaceuticals, Inc., incorporated on February 4, 2005, is a biopharmaceutical company. The Firm is engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Firm operates through pharmaceuticals segment. The Company’s products include lomitapide and metreleptin.

More recent Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) news were published by: Bostonglobe.com which released: “Aegerion Pharmaceuticals to merge with Canadian drug maker” on June 15, 2016. Also Fool.com published the news titled: “Why Aegerion Pharmaceuticals Is Crashing Today” on November 10, 2015. Bostonglobe.com‘s news article titled: “Aegerion to cut 13 percent of workforce” with publication date: July 20, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By kentuckypostne


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>